In an interview to CNBC-TV18, Arvind Bothra, Religare Enterprises shared his reading and outlook on the pharma sector. He spoke about the recent developments varios pharma compnaies like the Strides Arcolab and Mylan deal and the warning letter which Jubilant Life Sciences got from the US FDA.
Also Read: Jubilant Life tanks 10% on USFDA warning letter to US plant Talking about Strides Arcolab he further said that the deal with Mylan would be worth USD 1.5 billion excluding USD 250 million and around USD 500 million will be left for payment via special dividend.Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
